Inhibitor Therapeutics Inc INTI Stock Analysis

About Inhibitor Therapeutics Inc

SUBA-Itraconazole (which stands for "super bioavailability") is a patented formulation of itraconazole designed to improve the bioavailability of orally administered drugs that are poorly soluble. SUBA-Itraconazole has improved absorption and significantly reduced variability compared to generic Itraconazole, providing patients and prescribers with reduced intra- and inter-patient variability, enabling a more predictable clinical dose response and a reduction in the active drug quantity required to deliver therapeutic levels into the bloodstream. SUBA-Itraconazole is manufactured by Mayne Pharma under current Good Manufacturing Practice standards for HedgePath's use in clinical trials. An affiliate of Mayne Pharma is HedgePath's majority stockholder and the licensor of the SUBA-Itraconazole technology. About HedgePath Pharmaceuticals HedgePath Pharmaceuticals, Inc. is a pharmaceutical development company that discovers, develops and plans to commercialize innovative therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders. HedgePath Pharmaceuticals, Inc. is a pharmaceutical development company that discovers, develops and plans to commercialize innovative therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders. HedgePath is the exclusive U.S. licensee of SUBA-Itraconazole in certain fields. Clinical studies have shown SUBA-Itraconazole to have greater bioavailability than generic itraconazole, a drug that has been approved by FDA for the treatment of certain fungal infections. The Hedgehog signaling pathway is a major regulator of cellular processes in vertebrates, including cell differentiation, tissue polarity and cell proliferation. Based on published research, HedgePath believes that inhibiting the Hedgehog pathway could delay or possibly prevent the development and progression of certain cancers, such as prostate cancer, in humans. Leveraging research undertaken by key investigators in the field, HedgePath is exploring the effectiveness of SUBA-Itraconazole as an anti-cancer agent and to pursue its potential commercialization. HedgePath is headquartered in Tampa, Florida.